Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM, Pennings ERA, Kos M, Mutsaers PGNJ, Lugtenburg PJ, van Meerten T, van Doesum JA, Minnema MC, Jak M, van Dorp S, Vermaat JSP, van der Poel MWM, van Oijen MGH, Kuipers MT, Nijhof IS, Kersten MJ. Spanjaart AM, et al. Among authors: nijhof is. JCO Oncol Pract. 2023 Mar;19(3):e407-e416. doi: 10.1200/OP.22.00501. Epub 2022 Dec 12. JCO Oncol Pract. 2023. PMID: 36508702 Free PMC article.
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. Nijhof IS, et al. Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15. Blood. 2016. PMID: 27307294 Free article. Clinical Trial.
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib.
van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, van Dijk M, Raymakers R, Petersen E, de Witte M, de Jong N, Bellido M, Bär B, Meijer E, Kuball J. van der Wagen L, et al. Bone Marrow Transplant. 2018 Oct;53(10):1255-1262. doi: 10.1038/s41409-018-0158-9. Epub 2018 Mar 16. Bone Marrow Transplant. 2018. PMID: 29549292 Clinical Trial.
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.
Frerichs KA, Minnema MC, Levin MD, Broijl A, Bos GMJ, Kersten MJ, Mutis T, Verkleij CPM, Nijhof IS, Maas-Bosman PWC, Klein SK, Zweegman S, Sonneveld P, van de Donk NWCJ. Frerichs KA, et al. Among authors: nijhof is. Blood Adv. 2021 Dec 14;5(23):5128-5139. doi: 10.1182/bloodadvances.2021005220. Blood Adv. 2021. PMID: 34625791 Free PMC article. Clinical Trial.
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, de Rooij DM, van Meerloo J, Cloos J, Kootstra NA, Wouters D, Weijers SS, van Leeuwen EMM, Bontkes HJ, Tonouh-Aajoud S, Heemskerk MHM, Sanders RW, Roelandse-Koop E, Hofsink Q, Groen K, Çetinel L, Schellekens L, den Hartog YM, Toussaint B, Kant IMJ, Graas T, de Pater E, Dik WA, Engel MD, Pierie CRN, Janssen SR, van Dijkman E, Poniman M, Burger JA, Bouhuijs JH, Smits G, Rots NY, Zweegman S, Kater AP, van Meerten T, Mutsaers PGNJ, van Doesum JA, Broers AEC, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS. Haggenburg S, et al. Among authors: nijhof is. Blood Adv. 2022 Mar 8;6(5):1537-1546. doi: 10.1182/bloodadvances.2021006917. Blood Adv. 2022. PMID: 35114690 Free PMC article. Clinical Trial.
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Zweegman S, Kater AP, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, Beaumont T, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI Study Team. Haggenburg S, et al. Among authors: nijhof is. JAMA Oncol. 2022 Oct 1;8(10):1477-1483. doi: 10.1001/jamaoncol.2022.3227. JAMA Oncol. 2022. PMID: 35951338 Free PMC article.
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Rots N, van Beek J, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. Hofsink Q, et al. Among authors: nijhof is. EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. EClinicalMedicine. 2023. PMID: 37337616 Free PMC article.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: nijhof is. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Carfilzomib for relapsed and refractory multiple myeloma.
Groen K, van de Donk N, Stege C, Zweegman S, Nijhof IS. Groen K, et al. Among authors: nijhof is. Cancer Manag Res. 2019 Apr 2;11:2663-2675. doi: 10.2147/CMAR.S150653. eCollection 2019. Cancer Manag Res. 2019. PMID: 31037034 Free PMC article. Review.
42 results